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Introduction {#sec1}
============

Exocytosis is an essential process in all eukaryotic cells, defined as the delivery of intracellular contents such as hormones, mRNAs, and proteins between secretory vesicles and the plasma membrane (PM). The spatially controlled fusion of these secretory vesicles with the PM requires SNARE proteins. However, before vesicle fusion with the PM, vesicles must first be anchored to the membrane by the octameric exocyst complex. First identified in *S*. *cerevisiae*, using a variety of biochemical and genetic approaches ([@bib73], [@bib74], [@bib61]), the exocyst complex is an evolutionarily conserved macromolecular complex composed of Sec3, Sec5, Sec6, Sec8, Sec10, Sec15, Exo70, and Exo84. Evidence suggests that it is this exocyst complex that imparts spatial and temporal control of exocytosis and that such precision control is critical for a myriad of cellular processes, such as morphogenesis, cell cycle progression, primary ciliogenesis, cell migration, and tumor invasion ([@bib79]).

When it comes to spatial control, it appears that the process of exocytosis is highly polarized. Yeast genetics, and biochemical ([@bib7]) and structural studies using cryoelectron microscope and 3D molecular modeling ([@bib52]) in yeast have suggested that the exocyst complex is assembled in a hierarchical manner and that several such complexes may cooperatively ensure the fidelity in recruiting the vesicle to the appropriate exocytic site on the PM ([@bib63]). For example, in the budding yeast, the exocyst is localized to the emerging bud tip, where it mediates exocytosis for the asymmetric expansion of daughter cell surfaces during polarized cell growth. During cytokinesis, the exocyst is localized to the mother-daughter cell junction to mediate abscission ([@bib74], [@bib19], [@bib26], [@bib81]). Exo70p and Sec3p were identified as the key subunits of the octameric complex, which plays a pivotal role in targeting of the exocyst to specific sites on the PM ([@bib7]). Such polarized localization of Exo70p and Sec3p cannot be attributed to t-SNARE (target-Soluble NSF-Attachment Protein Receptor) proteins, because the latter distributed along the entire PM ([@bib8]). Who or what imparts polarity to the process of exocytosis remained unknown until systematic studies employing Exo70p mutants and yeast genetics pinpointed that a specific stretch of Exo70p (i.e., domain C) must interact with some other actin-independent polarity determinant ([@bib32]), which was subsequently identified as the multidomain polarity scaffold and bud emergence protein, Bem1p ([@bib43]). This Exo70p⋅Bem1p interaction was implicated in polarizing the process of vesicle exocytosis in yeast; binding-deficient mutants of Exo70p were incapable of tethering secretory vesicles to cortical sites specified by Bem1p ([@bib43]).

Although the fundamentals of exocytosis were discovered first in yeast, its existence and importance in mammals is widely accepted as a driver in multiple disease states in humans ([@bib50]), and insights into how the process is regulated in mammals remains unknown to date. As in yeast, the mammalian Exo70 has been the most studied subunit; these studies have revealed that although the composition of the canonical octameric exocyst component is essentially invariant ([@bib5]), there is, however, a remarkable degree of evolutionary flexibility to allow for specialization through diversity in exocytic mechanism and building more regulatory control along the way. For example, unlike yeast Exo70p, mammalian Exo70 interacts directly with Arp2/3 complex during cell migration and enhances actin cytoskeleton remodeling ([@bib84]). Mammalian Exo70 is also under the control of growth factors---epidermal growth factor stimulation triggers phosphorylation of Exo70 by ERK1/2 leading to enhanced octameric complex formation, matrix metalloproteinase (MMP) secretion, and cell invasion ([@bib82], [@bib28], [@bib48], [@bib29], [@bib44]). In addition, a switch between Exo70 isoforms has been reported in breast cancer that correlates with a switch from epithelial to mesenchymal transition ([@bib48]); the former is engaged in exocytosis, whereas the latter modulates actin dynamics. The fact that Exo70 was the only exocyst subunit found to correctly localize when overexpressed in mammalian epithelial cells ([@bib28], [@bib80]) suggested that Exo70 might be the critical component that recognizes a polarity determinant at the cell cortex. In the absence of any clear mammalian counterpart of yeast polarity scaffold Bem1p, it has been speculated that other mammalian polarity determinants may fulfill that role to facilitate Exo70 recruitment in mammals. The identity of such Bem1p counterpart in humans remains unknown.

Here we reveal that the multi-modular polarity scaffold Gα-interacting vesicle-associated protein (GIV, a.k.a, Girdin) ([@bib62], [@bib68], [@bib3]) fulfills the criteria to serve as the mammalian functional homolog of the yeast polarity determinant, Bem1p. The scaffolding function of GIV has been shown to mediate the purposeful dynamic "glue"-ing of diverse signaling pathways: GIV is a guanine nucleotide exchange factor (GEF) for trimeric GTPases, Gi ([@bib21], [@bib36]) and Gs ([@bib27]), a polarity scaffold that binds and modulates via G protein intermediates the aPKC/Par complexes ([@bib68], [@bib62]); it is a substrate of and major signaling conduit for multiple receptor and non-receptor tyrosine kinases ([@bib41], [@bib55], [@bib53]); serves as a signaling adaptor for growth factor ([@bib40]), integrins ([@bib46], [@bib39]), and other classes of receptors (reviewed in [@bib24]); and is an actin remodeler ([@bib18]) and a scaffold for polymerized microtubules ([@bib60], [@bib3]). Most of the work on GIV thus far has revealed its ability to serve as an integrator of multiple signaling pathways that enhances multiple fundamental cellular processes and how its dysregulation (overexpression and hyperactivation) favors cancer invasion and metastasis (reviewed in [@bib2]). This work not only sheds light into GIV\'s ability to enhance a key process that aids metastasis (i.e., polarized exocytosis of matrix metalloproteases) but also reveals how the modular makeup and functional diversity of GIV imparts the process of exocytosis features of polarity and context-dependent regulation by diverse signaling pathways.

Results and Discussion {#sec2}
======================

GIV and Bem1p Share Key Properties, Conserved Modes of Binding to Exo70 {#sec2.1}
-----------------------------------------------------------------------

We first began by looking for polarity scaffold proteins with the mammalian Exo70 interactome ([Figure S1](#mmc1){ref-type="supplementary-material"}) using Biological General Repository for Interaction Datasets (BioGRID; thebiogrid.org). A systematic analysis of all physical interactions of Exo70 revealed that among many coiled coil multi-modular proteins, it binds the mammalian polarity scaffold GIV (encoded by the gene CCDC88A), as revealed initially in a yeast 2-hybrid screen ([@bib9]) and validated later by us as a protein that colocalizes with (as determined by confocal immunofluorescence and *in situ* proximity ligation assays) and directly binds Exo70 ([@bib47]). We noted that although the modular makeup of GIV and Bem1p had very little in common ([Figure 1](#fig1){ref-type="fig"}A), GIV fulfilled some of the key functional criteria that were previously deemed as necessary for Bem1p to polarize exocytosis in yeast ([Figure 1](#fig1){ref-type="fig"}B). Furthermore, besides its ability to bind and modulate Par-polarity complexes, GIV presented numerous additional modules, functional features, and interesting interactions ([Figures 1](#fig1){ref-type="fig"}A and 1B). We hypothesized that GIV may be the long-sought evolutionary counterpart of Bem1p. Because Exo70 was proposed as the exocyst subunit that interacts with polarity determinants in mammalian cells ([@bib28], [@bib80]), we began first by comparing the abilities of Bem1p and GIV to bind yeast and human Exo70. We found that both GST-tagged human (hExo70) and yeast (Exo70p) Exo70 could bind full-length endogenous GIV ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Using recombinant His-tagged proteins in similar pull-down assays with GST-Exo70, we confirmed that the GIV⋅Exo70 interaction is direct and that the C terminus of GIV is sufficient (GIV-CT; [Figure 1](#fig1){ref-type="fig"}C). Although both Bem1p and GIV-CT could bind both yeast and human Exo70 proteins, each preferentially bound to its evolutionary counterpart ([Figures 1](#fig1){ref-type="fig"}C and 1D): GIV-CT binds four times as much to human Exo70 compared with yeast Exo70p ([Figure 1](#fig1){ref-type="fig"}C), whereas equimolar amounts of Bem1p binds two times as much to yeast Exo70p compared with human Exo70 ([Figure 1](#fig1){ref-type="fig"}D). These protein concentrations were chosen based on the published Kd of Bem1p with Exo70p ([@bib43]); concentrations of all human proteins (GIV and Exo70) were adjusted to molar equivalents to yeast counterparts.Figure 1Polarity Scaffolds GIV and Bem1p Share Key Properties and Display Conserved Modes of Binding to Exo70(A) Domain maps of the yeast (Bem1p \[top\]) and human (GIV/Girdin \[bottom\]) polarity scaffolds. Major interactions are annotated.(B) Table listing key properties of Bem1p that have been implicated in its ability to impart polarity to the process of exocytosis.(C) Recombinant His-GIV-CT (\~3 μg) was used in GST pull-down assays with GST, GST-hExo70 (human), and GST-Exo70p (yeast). Bound GIV was visualized by immunoblotting using anti-His mAb. Equal loading of GST proteins was confirmed by Ponceau S staining. Top right: bar graph displays fold change in binding. Error bars represent standard error of mean; ± SEM; n = 3; ∗∗∗p value = 0.001.(D) Recombinant His-Bem1p (\~3 μg) was used in GST pull-down assays with GST proteins as in (C). Bound Bem1p was visualized by immunoblotting using anti-His mAb. Equal loading of GST proteins was confirmed by Ponceau S staining. Bottom left: Bar graph displays fold change in binding. Error bars represent standard error of mean; ± SEM; n = 3; ∗∗p value = 0.01.(E--G) Pull-down assays as in (C) were carried out using either recombinant His-GIV-CT (E) or His-Bem1p (G) and various GST constructs ([@bib43]) lacking the indicated domains of Exo70 (yeast versus mouse comparison; (F) immobilized on glutathione beads. Bound GIV (E) or Bem1p (G) was visualized by immunoblotting using anti-His mAb. Equal loading of GST proteins was confirmed by Ponceau S staining.(H--J) Competition between GIV and Bem1p for binding to either Exo70p (yeast; H) or hExo70 (human; I) was assessed by carrying out pull-down assays adding (+) or not (−) the soluble His-GIV-CT and His-Bem1p proteins alone or simultaneously to GST-Exo70 proteins immobilized on glutathione beads. Bound GIV or Bem1p proteins were visualized by immunoblotting using anti-His mAb. (J) Schematic summarizing the cross-species binding of Bem1p and GIV to Exo70. The size and darkness of arrows indicate binding preference.

Prior work showed that although Bem1p forms an extended interface with Exo70p, domain C is the most critical part of Exo70 that is responsible for the interaction ([@bib43]). Using a series of previously validated Exo70p mutants, we confirmed that both Bem1p and GIV-CT form an extensive and similar interface with Exo70---although domain C is the major contributor, domains A, B, and D are also relevant ([Figures 1](#fig1){ref-type="fig"}E--1G). Despite the overall similarity in domain contributions, combination of multiple single point mutations on the surface of Exo70p that disrupts the Bem1p⋅Exo70 interaction ([@bib43]) did not seem to affect binding to GIV-CT ([Figure S2](#mmc1){ref-type="supplementary-material"}B). These findings are in keeping with the fact that mammalian and yeast Exo70 differ in both conformation and surface charge ([Figures 1](#fig1){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}C) and share low level of sequence conservation, which has been suggested as a basis for species-specific functions of the exocyst ([@bib57]). We also believe that these findings using Exo70p truncations and multi-point mutations are possibly real and not confounded by truncation/mutation-related artifacts (protein misfolding, denaturing, etc.) because the same constructs when used in earlier studies bound Rho3-GTP ([@bib43]).

In the absence of conserved amino acids across species, or any other structural clues, generating corresponding mutations in human Exo70 was not attempted. When we carried out competition assays with recombinant proteins to determine if the Bem1p⋅Exo70p and GIV⋅Exo70 interactions are mutually exclusive or inclusive, we found that both GIV and Bem1p could compete for yeast ([Figure 1](#fig1){ref-type="fig"}H) and human ([Figure 1](#fig1){ref-type="fig"}I) Exo70. These findings suggest that Bem1p and GIV may share the mechanism of binding and that their binding interfaces with Exo70 are either significantly overlapping or non-overlapping but pose significant steric hindrance. Regardless, these findings demonstrate that despite divergent modular makeup, both polarity scaffolds Bem1p (yeast) and GIV (mammals) can bind Exo70 via mechanisms that are shared (i.e., use of Domains C of Exo70 as major contributor). They both may use either same or distinct interfaces for binding Exo70, but nonetheless bind in a mutually exclusive manner. Although each can bind both yeast and human Exo70 proteins, they demonstrate species preference ([Figure 1](#fig1){ref-type="fig"}J).

GIV Is Required for Exo70 Localization, Polarized Exocytosis {#sec2.2}
------------------------------------------------------------

Because GIV\'s role in tumor cell invasion and its ability to promote cancer metastasis has been demonstrated *in vitro* ([@bib39], [@bib66], [@bib34]) and *in vivo* ([@bib34]) using MDA MB231 human breast cancer cells, we used the same cells and asked if GIV is required for the polarized delivery of cargo proteins, e.g., matrix metalloproteases that aid in tumor dissemination by degrading extracellular matrix (ECM). We first confirmed that depletion of GIV (∼85% depletion by small hairpin RNA \[shRNA\]; [Figure 2](#fig2){ref-type="fig"}B) does not change the levels of Exo70 or cortactin; the latter is a marker of invadosomes, which are subcellular actin-rich landmarks that are specialized for matrix degradation because of polarized exocytosis of proteinases ([@bib11], [@bib30]). We found that hemagglutinin (HA)-tagged Exo70 localized to the PM in control but not GIV-depleted cells ([Figures 2](#fig2){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A, top panel). In control cells, disruption of actin cytoskeleton with latrunculin B, a chemical that has been widely used for its ability to sequester G-actin and prevent F-actin assembly ([@bib58]), prevented fusion of Exo70-positive vesicles but did not impact their docking at specific sites on the PM; in GIV-depleted cells the vesicles were in disarray ([Figures 2](#fig2){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A, bottom panel; [Figure 2](#fig2){ref-type="fig"}C). These findings indicate that GIV is required for the localization of Exo70 to the PM and that such localization is actin independent.Figure 2GIV Is Required for Exo70 Localization and Polarized Exocytosis(A) Immunoblots of lysates of control (sh Control) and GIV-depleted (sh GIV) MDA MB231 cells.(B) Control (sh Control) and GIV-depleted (sh GIV) MDA MB231 cells expressing HA-Exo70 were treated (bottom) or not (top) with 25 μM latrunculin B for 24 h before fixation with PFA. Fixed cells were stained for HA and analyzed by confocal microscopy. Representative deconvolved images are shown. Scale bar, 10 μm. Arrowheads, PM localization.(C) Bar graphs show the % cells with PM localization of Exo70-HA. Error bars represent standard error of mean; ± SEM; n = ∼ 30 cells/assay, 3 independent assays. ∗∗p value \<0.01.(D) Cells in (B) exogenously expressing HA-Exo70 (green) and MT1-MMP-mCherry (red) were plated on gelatin-coated coverslips and fixed and stained with the invadosome marker cortactin (magenta). Representative deconvolved images are shown. Boxed area with grey interrupted line represents cell\'s center, likely invadosomes. Colored arrowheads track single exocytic events. Scale bar, 10 μm. Insets were analyzed by rendering 3D surface plots using ImageJ. Cortactin/MT1-MMP colocalization was determined by Pearson\'s correlation coefficient reaching a value of 0.71 ± 0.05 and 0.15 ± 0.04 in control and GIV-depleted cells, respectively, from four different experiments.(E) Cells in (B) exogenously expressing MT1-MMP-pHLuorin were plated on a layer of unlabeled gelatin and imaged by TIRF microscopy. Left: Still frames from a 10-min-long movie ([Videos S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). Each colored arrowhead marks one successfully exocytosed vesicle. Scale bar, 2.5 μm. Right: Bar graph shows the number of exocytic events that were encountered during the 10-min-long movie in (D). N = ∼ 5--10 cells/assay. Error bars represent standard error of mean; ± SEM. ∗p value \<0.05.(F) Cells in (B) were plated for 5 h on fluorescein isothiocyanate (FITC)-conjugated cross-linked gelatin (green) and then fixed and stained for F-actin (Phalloidin; red). (Left) Representative images are shown. Scale bar, 10 μm. (Right) Bar graphs display the % of cells that showed degradation of gelatin. N = ∼100--200 cells/experiment × 3. Error bars represent standard error of mean; ± SEM. ∗∗p value = 0.001.

Video S1. Time-Lapse TIRF Images of a Control (sh Control) MDA-MB231 Cells, Related to Figure 2ECells transiently expressing MT1-MMP-pHluorin show real-time exocytic events. Images were acquired over 10 min. The movie was acquired at exposure time of 100 ms and with 1 pixel corresponding to 160 nm

Video S2. Time-Lapse TIRF Images of a GIV-Depleted (by shRNA) MDA-MB231 Cells, Related to Figure 2EGIV-depleted cells transiently expressing MT1-MMP-pHluorin shows real-time exocytic events. Images were acquired over 10 min. The movie was acquired at exposure time of 100 ms and with 1 pixel corresponding to 160 nm

Next, to analyze how Exo70 localization may impact polarized exocytosis of proteases to invadosomes, we co-transfected the MDA MB231 cells with HA-Exo70 and a previously validated MT1-MMP-mCherry construct ([@bib71]), plated them on gelatin, and looked for the co-localization of MT1-MMP, Exo70, and cortactin. Again, HA-Exo70 localized to the PM in the presence of GIV, but significantly less in its absence ([Figure 2](#fig2){ref-type="fig"}D; Region \#1). Colocalization between MT1-MMP-mCherry and cortactin was easily detected in control cells, but significantly reduced in cells without GIV ([Figures 2](#fig2){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}B; Region \#2 and 3D plot of invadosome). These findings indicate that GIV is required for efficient localization of proteases near invadosomes. We also noted that despite similar levels of expression of cortactin in the GIV-depleted cells ([Figure 2](#fig2){ref-type="fig"}A), the localization of cortactin at the sub-nuclear plane at the center of these cells was consistently impaired ([Figure 2](#fig2){ref-type="fig"}D). To assess the dynamics of polarized exocytosis in real time, we used a pH-sensitive MT1-MMP-pHluorin construct ([@bib56]), which is fluorescent only at an extracellular pH of 7.4. Prior studies using this construct and total internal reflection fluorescence (TIRF) live-cell microscopy have demonstrated that MT1-MMP-pHluorin demonstrates dot-like localization at the substrate-attached cell side, reminiscent of invadosomes ([@bib17], [@bib64]). When we carried out TIRF microscopy on control and GIV-depleted MDA MB231 cells, we found that the number of exocytic events were significantly lower in the latter ([Figure 2](#fig2){ref-type="fig"}E; [Videos S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}), and that they were not clustered near the center of the cell ([Figure 2](#fig2){ref-type="fig"}E; interrupted white square). Consistent with these findings, compared with controls cells fewer % of GIV-depleted cells demonstrated gelatin degradation ([Figure 2](#fig2){ref-type="fig"}F). Together, these findings suggest that GIV is required for the localization of Exo70 to specific sites at the PM, and for the polarized exocytosis of MT1-MMP at the invadosomes. Because the polarized exocytosis of MT1-MMP and the formation, maturation, and functions of the invadosome (which is marked by cortactin) are known to be intertwined ([@bib35], [@bib56], [@bib11], [@bib10], [@bib1]), our findings also suggest that GIV-dependent exocytosis of the protease may impact the dynamics of invadosomes and efficient degradation of ECM.

A Short Linear Motif on C Terminus Mediates GIV\'s Interaction with Exo70 {#sec2.3}
-------------------------------------------------------------------------

To pinpoint the role of GIV in polarized exocytosis, we set out to identify mutant(s) of GIV that may not bind Exo70. Previously, using domain mapping studies the Exo70p-binding domain of Bem1p was narrowed down to amino acids 309--510, which includes three-quarters of the PX domain, half of the PB1 domain, and the region connecting them (see [Figure 1](#fig1){ref-type="fig"}A) as both necessary and sufficient ([@bib43]). Because Bem1p and GIV appeared to share the mechanism of binding to Exo70, via what appears to be extensive binding interfaces ([Figures 1](#fig1){ref-type="fig"}H and 1I), we hypothesized that the interactions could be sensitive to some key residues. When Bem1p and GIV aligned, we noticed that they have very little similarity in sequences, except for a short stretch of sequence within the PX domain of Bem1p, ^320^DFYD^323^ ([Figures 3](#fig3){ref-type="fig"}A and 3B). When we superimposed two previously solved structures of Bem1p, we noted that the phenylalanine (F) within this sequence exhibits flexibility ([Figure 3](#fig3){ref-type="fig"}A). We targeted this putative short linear interaction motif (SLIM, ^1741^DFYD^1744^) in GIV either by selectively replacing the Phe \> Ala (F^1742^A) or by replacing the motif with Ala at three of the four positions (AAxA). Both mutants did not bind GST-Exo70 ([Figure 3](#fig3){ref-type="fig"}C). Next we carried out a series of mutations within and flanking the SLIM and noted that several of them impaired binding of GIV to Exo70 ([Figure 3](#fig3){ref-type="fig"}D), demonstrating that regardless of potentially extensive contact sites, the GIV⋅Exo70 interaction is sensitive to point-directed mutagenesis.Figure 3A Short Linear Motif on C Terminus Mediates GIV\'s Interaction with Exo70(A) Two views of the two solved crystal structures of PX domain of Bem1p (PDB:[2V6V](pdb:2V6V){#intref0025}, [@bib70]; PDB:[2CZO](pdb:2CZO){#intref0030}, unpublished), showing the position and orientation of key residues Phe (F)321 and Tyr (Y)322 on Bem1p that are within the previously identified stretch of amino acids 309--510 that is both necessary and sufficient for binding to Exo70p.(B) Sequence alignment showing a short linear "DFYD" motif that is conserved between GIV and Bem1p.(C and D) Recombinant WT and mutant His-GIV-CT (∼3 μg) proteins were used in GST pull-down assays with GST or GST-hExo70 (human). Two mutants in panel C are used throughout the remaining study to investigate the role of the GIV-Exo70 interaction. Other mutants in panel D were used to characterize the Exo-70-binding motif on GIV. Bound GIV was visualized by immunoblotting (IB) using anti-His monoclonal antibody (mAb). Equal loading of GST proteins was confirmed by Ponceau S staining.(E) Sequence-based prediction of mutations in GIV (top; R1742»L) and Bem1p (bottom; F312»A) that should enhance and reduce binding to GST-Exo70p (yeast), respectively.(F) Recombinant His-GIV-CT WT or R1742»L mutant was used in GST pull-down assays with GST or GST-hExo70 (human). Bound GIV was visualized by immunoblotting using anti-His mAb.(G) Recombinant His-Exo70p was used in GST pull-down assays with GST or GST-Bem1p WT or F312»A mutant. Bound Exo70p was visualized by immunoblotting using anti-His mAb.

The sequence alignment also predicted mutations that would improve GIV\'s ability to bind yeast Exo70p (i.e., R^1745^L) or those that might impair Bem1p′s ability to bind Exo70p (F^321^A) ([Figure 3](#fig3){ref-type="fig"}E). We found both predictions to be true---a mutant GIV (R^1745^L) bound Exo70p stronger than GIV-wild-type (WT) ([Figures 3](#fig3){ref-type="fig"}F and [S4](#mmc1){ref-type="supplementary-material"}A). Similarly, the F321A mutant Bem1p did not bind Exo70p ([Figure 3](#fig3){ref-type="fig"}G). These findings provide further evidence that although the interactions between GIV or Bem1p is complex and may occur via an extensive interface, and that the mechanisms of these interactions in yeast and mammals are divergent for the most part, the SLIM we identified in this work may represent an evolutionary conserved mechanism ([Figure S4](#mmc1){ref-type="supplementary-material"}B). This Exo70-binding SLIM, localized within the C terminus of GIV, adds to the gathering catalog of SLIMs used by GIV to scaffold diverse signaling components ([Figure S4](#mmc1){ref-type="supplementary-material"}C).

Exo70 Binding-Deficient GIV Mutant Fails to Deliver MT1-MMP to Invadosomes {#sec2.4}
--------------------------------------------------------------------------

We next asked if the phenotypes we observed previously ([Figure 2](#fig2){ref-type="fig"}) were because of GIV\'s ability to bind Exo70. To this end, we generated MDA MB231 cell lines in which endogenous GIV was depleted by shRNA before being restored with full-length GIV either WT or the Exo70 binding-deficient GIV mutant AAxA ([Figure 4](#fig4){ref-type="fig"}A) and used them in similar assays as before. We found that compared with cells expressing GIV-WT, those expressing the binding-deficient AAxA GIV mutant showed impaired localization of HA-Exo70 at the PM ([Figure 4](#fig4){ref-type="fig"}B); colocalization of both Exo70 and MT1-MMP-mCherry to cortactin-positive invadosomes ([Figure 4](#fig4){ref-type="fig"}C); rate of exocytic events, as determined by TIRF microscopy on cells expressing MT1-MMP-pHluorin ([Figures 4](#fig4){ref-type="fig"}D and 4E; [Videos S3](#mmc4){ref-type="supplementary-material"}, [S4](#mmc5){ref-type="supplementary-material"}, and [S5](#mmc6){ref-type="supplementary-material"}); and gelatin degradation ([Figures 4](#fig4){ref-type="fig"}F and 4G). These results were also validated using another Exo70-binding deficient mutant, F^1742^A ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5C and [S6](#mmc1){ref-type="supplementary-material"}). Key findings were also reproduced in HeLa cells ([Figures S7](#mmc1){ref-type="supplementary-material"}A--S7C), which have been widely used in the past decade as the cellular model system of choice to study GIV\'s functions. These findings indicate that the GIV⋅Exo70 interaction may be critical for the localization of Exo70 to vesicle tethering sites at the PM and for the polarized exocytosis of MT1-MMP proteases at or near the invadosomes of cells.Figure 4Exo70-Binding-Deficient Mutant GIV Fails to Deliver MT1-MMP to Invadosomes(A) Immunoblots of lysates of control (sh Control) and GIV-depleted (sh GIV) MDA MB231 cells stably expressing GIV-FLAG WT and exo70-binding deficient AAxA mutant constructs. See also [Figure S5](#mmc1){ref-type="supplementary-material"}A.(B) GIV-depleted (sh GIV) MDA-MB-231 cells stably expressing GIV-WT or GIV-AAxA mutant were transfected with HA-Exo70 and were either treated (top) or not (bottom) with 25 μM latrunculin B for 24 h before fixation with PFA. Fixed cells were stained for HA and analyzed by confocal microscopy. Representative deconvolved images are shown. Arrowheads, PM localization. Unusually large membrane vesicles (see inset) were noted in mutant cells, but PM localization was impaired. Scale bar, 10 μm.(C) Cells in (B) transfected with HA-Exo70 (green) and MT1-MMP-mCherry (red) were plated on gelatin-coated coverslips, fixed, and stained with the invadosome marker cortactin (magenta). Representative deconvolved images are shown. Insets were analyzed by rendering 3D surface plots using ImageJ. See also [Figure S5](#mmc1){ref-type="supplementary-material"}B for F1742A mutant GIV. Cortactin/MT1-MMP colocalization was determined by Pearson\'s correlation coefficient reaching a value of 0.87 ± 0.07 and 0.35 ± 0.02 in GIV-WT and GIV-AAxA cells, respectively, from three different experiments. Scale bar, 10 μm.(D) Cells in (B) were transfected with MT1-MMP-pHLuorin and were plated on a layer of unlabeled gelatin and imaged by TIRF microscopy. Each colored arrowhead tracks one vesicle. Still frames from a 10-min-long movie ([Videos S3](#mmc4){ref-type="supplementary-material"} and [S4](#mmc5){ref-type="supplementary-material"}). Scale bar, 2.5 μm. See also [Figure S5](#mmc1){ref-type="supplementary-material"}C for F1742A mutant GIV.(E) Bar graph shows the number of exocytic events that were encountered during the 10-min-long movie in (D). N = \~ 5--10 cells/assay. Error bars represent standard error of mean; ± SEM. ∗∗p value = 0.01.(F) Cells in (B) were plated for 5 h on FITC-conjugated cross-linked gelatin (green) and then fixed and stained for F-actin (Phalloidin; red). Representative images are shown. Scale bar, 10 μm. See also [Figure S6](#mmc1){ref-type="supplementary-material"} for F1742A mutant GIV.(G) Bar graphs display the % of cells that showed degradation of gelatin. N = \~100--200 cells/experiment × 3. Error bars represent standard error of mean; ± SEM. ∗∗∗p values = 0.001.

Video S3. Time-Lapse TIRF Images of a GIV-Depleted MDA-MB231 Cell Stably Expressing GIV-WT-FLAG, Related to Figure 4DGIV-depleted cells rescued with GIV-WT (stably) and transiently expressing MT1-MMP-pHluorin shows real-time exocytic events. Images were acquired over 10 min. The movie was acquiredat exposure time of 100 ms and with 1 pixel corresponding to 160 nm

Video S4. Time-Lapse TIRF Images of a GIV-Depleted MDA-MB231 Cell Stably Expressing a Exo70 Binding-Deficient GIV-AAxA-FLAG Mutant, Related to Figure 4DGIV-depleted cells rescued with GIV-mutant and transiently expressing MT1-MMP-pHluorin show real-time exocytic events. Images were acquired over 10 min. The movie was acquired at exposure time of 100 ms and with 1 pixel corresponding to 160 nm

Video S5. Time-Lapse TIRF Images of a GIV-Depleted MDA-MB231 Cell Stably Expressing Another Exo70 Binding-Deficient GIV-F1742A-FLAG Mutant, Related to Figure 4 and S5CGIV-depleted cells rescued with GIV-mutant and transiently expressing MT1-MMP-pHluorin show real-time exocytic events. Images were acquired over 10 min. The movie was acquired at exposure time of 100 ms and with 1 pixel corresponding to 160 nm.

Cells Expressing the Exo70-Binding-Deficient Mutant GIV Fails to Spread, Degrade Matrix, and Invade {#sec2.5}
---------------------------------------------------------------------------------------------------

Next we asked how the GIV⋅Exo70 interaction impacts cellular phenotypes that have been previously attributed to exocytosis of either membrane or proteases, e.g., cell spreading and invasion through the basement membrane ECM, but not impact adhesion; the latter is primarily mediated by integrins and is independent of exocytosis ([Figure 5](#fig5){ref-type="fig"}A). We hypothesized that cells expressing a mutant GIV that cannot bind Exo70 may adhere normally but may not spread or invade efficiently through the ECM. Cell adhesion assays confirmed that depletion of GIV impairs adhesion on collagen-coated surface ([Figure 5](#fig5){ref-type="fig"}B), which is in keeping with prior work by others and us showing that GIV modulates integrin signaling ([@bib39], [@bib38], [@bib46]). Cells expressing either GIV-WT or the binding-deficient GIV-AAxA mutant adhered to the collagen to similar extents as control cells ([Figure 5](#fig5){ref-type="fig"}B), indicating that the cell adhesion occurs independent of the GIV⋅Exo70 interaction. As for cell spreading, we analyzed spreading at or beyond ∼30 min, a phase of spreading that requires membrane exocytosis and is proteolysis dependent ([Figure 5](#fig5){ref-type="fig"}C). We found that although both GIV-WT and GIV-AAxA cells adhered equally well to collagen-coated surfaces ([Figure 5](#fig5){ref-type="fig"}B), the latter showed significant impairment in cell spreading ([Figures 5](#fig5){ref-type="fig"}D and 5E), indicating that cell spreading requires an intact GIV⋅Exo70 interaction. Haptotaxis assays carried out across a 0% to 10% serum gradient ([Figure 5](#fig5){ref-type="fig"}F) showed that depletion of GIV impairs cell invasion; however, such impairment is rescued by GIV-WT, but not the Exo70 binding-deficient GIV-AAxA mutant ([Figures 5](#fig5){ref-type="fig"}G and 5H). These findings demonstrate that the GIV⋅Exo70 interaction is required for key phenotypes of cancer cells that require efficient polarized exocytosis of proteases that degrade the ECM and aid in tumor dissemination.Figure 5Cells Expressing Exo70-Binding-Deficient Mutant GIV Adhere, but Fail to Spread, Degrade Matrix, and Invade(A) Schematic summarizing how polarized exocytosis of membrane and cargo (in this case MT1-MMP) impacts cell adhesion, spreading, and invasion. Check, dependent; cross, independent.(B) MDA-MB 231 cell lines were analyzed for cell adhesion by growing on poly-D-lysine-coated surface, resuspending, and then plating on 12-well collagen-coated plates for 30 min before fixing with 4% PFA and staining with crystal violet. Cells were visualized and imaged by light microscopy. (Left) Representative images are shown. Scale bar, 250 μm. (Right) Bar graphs display the relative numbers of adherent cells per field, as determined using ImageJ. Error bars represent standard error of mean; ± SEM (n = 4); ∗∗p value \< 0.01; ns, not significant.(C) Schematic summarizing the phases of cell spreading during adhesion.(D) Adherent MDA-MB 231 cells in (B) were further analyzed for attachment-induced cell spreading at higher magnification. Representative images are shown. Scale bar, 250 μm.(E) Bar graphs display the quantification of % spreading in (D). Error bars represent standard error of mean; ± SEM (n = 4); ∗∗∗∗p value \< 0.0001.(F) Schematic diagram showing the serum gradient-induced haptotaxis assay conditions used in (G and H).(G) MDA-MB 231 cell lines in (A) were analyzed for the ability to invade through Matrigel-coated transwells. The number of cells that successfully invaded within 24 h was imaged. Representative images are shown. Scale bar, 250 μm.(H) Bar graphs display the number of invading cells in (G), as determined using ImageJ. Error bars represent standard error of mean; ± SEM (n = 4); ∗∗∗p value \< 0.001, ∗∗∗∗p value \< 0.0001.

Components of Polarized Exocytosis Synergize during Tumor Metastasis {#sec2.6}
--------------------------------------------------------------------

We next asked if the interaction between GIV and Exo70 we report here and the impact of such interaction on the invasive properties of tumor cells can be meaningful when assessing tumor behavior and/or prognosticating clinical outcome. To discern if the levels of expression of Exo70 or GIV alone could impact one of the most important readouts of cancer aggressiveness, i.e., metastasis-free patient survival, we chose to study a pooled cohort of patients ([GSE2034](ncbi-geo:GSE2034){#interref35}, [GSE2603](ncbi-geo:GSE2603){#interref40} and [GSE12276](ncbi-geo:GSE12276){#interref45}; [@bib54], [@bib6], [@bib78]) with breast cancers. These cohorts are unique because the patients did not receive adjuvant chemotherapy, and hence, metastatic progression in them reflects natural disease progression and not resistance/selection under treatment. Samples were divided into "low" and "high" subgroups with regard to Exo70 (EXOC7) and GIV (CCDC88A) gene expression levels using the StepMiner algorithm ([@bib67]), implemented within the hierarchical exploration of gene expression microarrays online (HEGEMON) software ([@bib15], [@bib76]). Kaplan-Meier analyses of the disease-free survival showed that Exo70 and GIV had opposing impact on outcome ([Figure 6](#fig6){ref-type="fig"}A)---high levels of GIV expression carried a grave prognosis, i.e., a shorter metastasis-free survival, which is consistent with numerous prior studies (reviewed in [@bib22]). By contrast, high expression of Exo70 carried a better prognosis, i.e., a longer metastasis-free survival ([Figure 6](#fig6){ref-type="fig"}A); this is also consistent with prior findings that an epithelial isoform of Exo70, which is the isoform that is primarily responsible for exocytic secretions, inhibits tumor metastasis in mice ([@bib48]).Figure 6Polarity Scaffold GIV (CCDC88A), Matrix Metalloprotease MT1-MMP, and Exocyst Complexes Synergize during Metastasis(A) An overlay of Kaplan-Meier curves for metastasis-free survival over time among 572 patients (3 independent cohorts, pooled, [@bib54], [@bib6], [@bib78]) who did not receive adjuvant therapy segregated into high versus low levels of exo70 (EXOC7) or GIV (CCDC88A) in primary tumors.(B and C) Statistical interaction (synergy between variables) is measured in the Cox proportional hazards regression model for EXOC7 (exo70) (B), CCDC88A (GIV) (C), and all mammalian polarity scaffold proteins, including CCDC88A (GIV). Coefficient of the interaction term in Cox regression models is plotted with 95% confidence interval that demonstrates the significance of the statistical interaction. ∗p = 0.05, ∗∗p = 0.01. Red and green asterisks denote shorter or longer metastasis-free survival, respectively.(D and E) Statistical interaction (synergy between variables) is measured in the Cox proportional hazards regression model as in (B and C) for EXOC7 (exo70) (D), CCDC88A (GIV) (E), and mammalian proteins known to be involved in or influence the exocytosis of MT1-MMP. Red and green asterisks denote shorter and longer metastasis-free survival, respectively.(F) Schematic summarizing only those interactions with EXOC7 that reduced metastasis-free survival. Purple, genes that encode polarity proteins; pink, others. Network-based prediction of RHOQ (TC10) as the RHO GTPase counterpart in mammals that synergistically interacts with CCDC88A (GIV).(G and H) (G) Schematic summarizing the constructs used in (H) to assess nucleotide state-dependent interaction between TC10 and GIV. GST pull-down assays were carried out using lysates of COS7 cells as source of TC10-HA WT or constitutively active (QL) or inactive (TN) mutants with GST or GST-GIV-CT. Bound proteins were assessed with anti-HA mAb.(I) MDA MB231 cells exogenously expressing TC10-WT-QL (green) were fixed and stained for endogenous GIV (red). Representative images of transfected cells are shown. Scale bar, 10 μm. Red and green panels are shown in gray scale. Insets (Box1, 2) were analyzed for colocalization by line scans to generate RGB plots using ImageJ. TC-10/GIV colocalization was determined by Pearson\'s correlation coefficient reaching a value of 0.86 ± 0.06 from three different cultures.

We next sought to determine if the levels of expression of either GIV or Exo70 and other genes that encode major polarity scaffolds ([@bib42]) interact synergistically as independent variables to impact survival of patients. To this end, we carried out a Cox proportional hazards model ([@bib14]), which is a regression model that is commonly used as a statistical method for investigating the effect of several variables upon the time it takes for a specified event to happen, in this case, metastasis. We found that besides GIV/CCDC88A, Exo70 significantly and negatively interacts with multiple members of the Par, Scribble, and Crumbs family of polarity scaffolds ([Figure 6](#fig6){ref-type="fig"}B), in that, high levels of expression of each of these scaffolds in the setting of high Exo70 expression was sufficient in shortening metastasis-free survival. Of all those polarity scaffolds that interacted with Exo70, only DLG5 continued to show positive synergistic interactions with CCDC88A (GIV) ([Figure 6](#fig6){ref-type="fig"}C), in that, high levels of expression of DLG5 in the setting of high GIV expression further shortened metastasis-free survival. Next we asked how Exo70 or GIV interacts with other components of the exocytic machinery, i.e., core trafficking components (i.e., monomeric GTPases Rabs, Arf6), focal adhesions cytoskeleton and Rho GTPases (Paxillin, PXN; Actin, ACTB; TC10, RHOQ; Rho-associated kinase, ROCK1), cargo (MT1-MMP, MMP14), and receptors (ITGB1 and EGFR). We found that whereas many components may negatively interact with Exo70 ([Figure 6](#fig6){ref-type="fig"}D), only TC10 GTPase (RHOQ) positively and synergistically interacts with GIV to shorten metastasis-free survival ([Figure 6](#fig6){ref-type="fig"}E).

Based on all gene pairs tested, we computed the interactome for Exo70 that shortens metastasis-free survival ([Figure 6](#fig6){ref-type="fig"}F). The interactome enabled two major predictions. (1) Polarized exocytosis during metastasis may require Exo70 to synergize with both GIV and DLG5. Because GIV binds DLG5 and their interaction regulates the formation of invadopodia ([@bib37]), and DLG5 in turn engages with tSNARE syntaxin-4 ([@bib59]) to enable the exocytosis ([@bib77]), it is possible that DLG5 also impacts polarized exocytosis. (2) The interactome predicted that TC10, a close relative of Cdc42 is a likely candidate Rho-superfamily GTPase that may cooperate with GIV during the exocytosis of MT1-MMP.

We asked if GIV\'s C terminus interacts with TC10 and if such interaction is regulated by its nucleotide-bound (activity) state. Using previously validated TC10 constructs ([@bib12]) that mimic active (QL) or inactive (TN) conformations ([Figure 6](#fig6){ref-type="fig"}G) in pull-down assays with GST-GIV-CT we first confirmed that GIV exclusively binds active, but not the inactive, GTPase ([Figure 6](#fig6){ref-type="fig"}H). To translate the relevance of these *in vitro* findings to cells, we tested the impact of TC10 on the localization of endogenous full-length GIV, as determined by confocal immunofluorescence on fixed cells. Transfection of active QL mutant, but not WT TC10, was sufficient to enhance the localization of GIV to focal adhesion and/or invadosome-like peripherally located structures ([Figures 6](#fig6){ref-type="fig"}I and [S8](#mmc1){ref-type="supplementary-material"}), where they colocalized ([Figure 6](#fig6){ref-type="fig"}I, RGB plots). These findings are in keeping with the fact that mammalian Exo70 has been shown to directly interact with active TC10 ([@bib33]) and that activation of TC10 has been linked with the formation and functions of the invadosome. Together, our findings suggest that TC10 may be the evolutionary counterpart that binds GIV, and in doing so, may fulfill the role that cdc42p has been shown to perform alongside the Exo70p⋅Bem1p complex in yeast ([@bib43]).

Conclusions {#sec2.7}
-----------

The major discovery we report herein is the mechanism and consequences of a direct interaction between GIV and Exo70, and its impact on polarized exocytosis of matrix metalloprotease MT1-MMP. Using selective single point mutants of GIV that are incapable of binding Exo70, we chart the two major consequences of this GIV⋅Exo70 interaction. First, the GIV⋅Exo70 interaction impacts our understanding of exocytosis in mammalian cells. Findings reveal that GIV imparts polarization to the process of exocytosis. How does GIV do so? Previously, we showed that GIV\'s ability to activate trimeric GTPase Gαi is critical for its ability to enhance insulin-stimulated exocytosis of glucose transporter, GLUT4-storage vesicles ([@bib47]), which in part accounts for GIV\'s ability to maintain insulin sensitivity in skeletal muscle cells ([@bib49]). Others have demonstrated that the same G protein regulatory module is essential for GIV\'s ability to activate Par3/6/aPKC polarity complexes ([@bib68]). Because the Par3/6/aPKC complexes are highly versatile in their ability to orchestrate all forms of cell polarity, e.g., front-rear, apical-basal, planar cell, and polarity during migration ([@bib72]), and positive feedback loop signals are essential for the amplification of stochastically arising clusters of polarity factors that create and maintain such forms of polarity ([@bib51]), we propose that GIV enables polarized exocytosis in a bipartite manner: its ability to bind Exo70 imparts polarity and its ability to activate the Par3/6/aPKC polarity complexes via G protein intermediates (i.e., "free" Gβˠ dimers) serves as the positive feedback loop. Furthermore, GIV has been shown to use "free" Gβˠ intermediates to activate Rho-GTPases ([@bib39]) and to terminate Arf-GTPase signaling on endomembranes ([@bib45]), which may serve as additional positive and negative feedback loops. Such feedback loops have been shown to be critical for imparting robustness to the process of polarized exocytosis in yeast ([@bib31]): a positive feedback occurs wherein Cdc42p⋅GTP at the membrane can recruit the cytoplasmic Bem1p complex, which generates more Cdc42p⋅GTP from local Cdc42p⋅GDP by GEF-catalyzed exchange; a negative feedback loop enables dispersal of the polarity complexes by affecting the duration of activation of Cdc42p⋅GTP or phosphoinhibition of Bem1p. Whether GIV is at the crossroads of these regulatory loops with the Rho-GTPase TC10 or Rab/Arf-GTPases and what might be the exact mechanism(s) that impart regulatory control and robustness to the mammalian polarized exocytic machinery remain unknown. Regardless, GIV\'s multi-modular makeup (see [Figure 1](#fig1){ref-type="fig"}A), its functional diversity ([@bib2]), its growing catalog of phosphomodifications (including the "Y" within the Exo70-binding DFY^1743^D motif, see [Figure 3](#fig3){ref-type="fig"}; [phosphosite.org](http://phosphosite.org){#intref0010}), and its ability to integrate signals at the cross-roads of diverse types of signaling pathways (reviewed in [@bib24]) tempts us to speculate that its association with Exo70 may impose intricate regulatory control over the mammalian polarized exocytic machinery making it more precise, context-dependent, versatile, and adapted to the needs of multi-cellular organisms. In keeping with this assumption, it is noteworthy that the yeast polarity scaffold Bem1p has no known homologs in any multicellular organisms ([@bib43]), whereas GIV ([@bib13]) and its associated aPKC/Par3/6 complexes ([@bib75]) are absent in yeast and co-evolved only in worms and flies and highly conserved in mammals. Thus, our findings reveal the extent of evolutionary divergence in the polarized exocytic machinery from yeast to mammals (see legend, [Figure 7](#fig7){ref-type="fig"}); although the octameric exocyst complex remained constant, each component in yeast is replaced by its functional counterpart in mammals, beginning with an abrupt change in the polarity determinant coinciding with the onset of multicellular life forms. Although our findings suggest that the GIV⋅Exo70 co-complex may constitute the core component that imparts polarity to exocytosis, these may not be sufficient. It is noteworthy that just like Bem1p is not the only component affecting Exo70 localization in yeast (PI~4,5~P~2~, Cdc42, Rho1 and actin all play significant roles), GIV may not be the only component affecting polarized exocytosis in mammalian cells and Par/aPKC complexes, TC10, actin, and others may contribute significantly.Figure 7Components of Polarized Exocytosis Display an Evolutionary Advancement from Yeast to Mammals(A and B) Schematics summarizing the components of exocytosis in yeast (A) and mammals (B). Mammalian counterparts of all yeast components are represented using the same symbols. The octameric exocyst complex is conserved, whereas the polarity scaffolds Bem1p and GIV are divergent, alongside the previously annotated key components of the exocytic machinery. sec4p in yeast is replaced by Rabs in mammals, whereas the sec4p GAP (Msb2/3p) is replaced by the corresponding Rab-GAP, AS160, which has been previously shown to be activated by the GIV-dependent Class 1 PI3K » Akt signaling cascade ([@bib49]).

Second, the GIV⋅Exo70 interaction impacts our understanding of the pro-metastatic role of GIV in diverse cancers and how it impacts key tumor cell behaviors that are dependent on proteolysis. Because GIV modulates integrin/FAK signaling via G protein intermediates ([@bib39], [@bib38], [@bib47]), and because integrins and MT1-MMPs regulate each other\'s activity, trafficking, and signaling to integrate events in the extracellular milieu ([@bib25], [@bib16], [@bib4], [@bib20], [@bib83], [@bib69]), it is possible that GIV\'s C terminus may help in such process of integration. However, to begin to entertain that possibility or test it, an in-depth insight into how GIV binds integrins and how such binding impacts the GIV⋅Exo70 interaction is required first. Another issue that remains unexplored here is how the GIV⋅Exo70 complex may be dysregulated in cancers. Increased tyrosine-based signaling and hyperphosphorylation of GIV at Y1743 may impact the GIV⋅Exo70 interaction directly. Alternatively, because both GIV ([@bib65], [@bib23]) and Exo70 ([@bib48]) have been shown to have alternative isoforms, pre-mRNA splicing may derail the GIV⋅Exo70 interaction or alter its functions indirectly. For example, in the case of Exo70, unlike the epithelial isoform that inhibits tumor metastasis, a mesenchymal isoform aids in tumor metastasis in an exocytosis-independent manner ([@bib48]); the latter promotes tumor cell invasion by interacting with the Arp2/3 complex and stimulating actin branching in lamelipodia and invadopodia. Because GIV is a *bona fide* actin remodeler that impacts actin dynamics ([@bib34], [@bib18]), it is possible that the GIV⋅(mesenchymal)Exo70 complex may collaboratively enhance these actin-based processes.

Limitations of the Study {#sec3}
========================

As for the limitations of this study, although we used MT1-MMP as an example of a cargo in our experiments, GIV\'s ability to regulate such a fundamental component of exocytosis (Exo70) may affect the exocytosis of other cargo proteins, which extend beyond transmembrane proteases, such as receptors (e.g., RTKs and integrins) and other soluble cargo proteins. Although defining the complete inventory of the impacted cargo proteins is beyond the scope of this work, ongoing proteomics/metabolomics-based studies are expected to unravel that list. Similarly, we have not delineated the exact mechanism and dynamics of the interplay between MT1-MMP, TC10, cortactin, and GIV and how that impacts invadosome formation, function, and turnover; because GIV is an actin remodeler ([@bib34], [@bib18]), it is likely that GIV may have a significant effect on the functions of multiple components that coordinately regulate this critical structure used by invasive cancer cells.

In conclusion, this work not only sheds light into GIV\'s ability to enhance a key process that aids metastasis (i.e., polarized exocytosis of matrix metalloproteases) but also reveals how the modular makeup and functional diversity of GIV imparts the process of exocytosis features beyond polarity; it represents an evolutionary advancement of the process by adding layers of regulatory control by diverse signaling pathways.
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